Early-stage investors have been among the biggest backers of health tech companies focused on women’s health conditions, CNBC reports. Venture capital funding for so-called Femtech has tripled since 2015 from just over $600 million to nearly $1.9 billion last year, according to Pitchbook data. Yet, analysts say overall investment in women’s health remains underfunded. Beyond breast cancer, female health conditions garnered just 1% of pharmaceutical research funding in 2020, according to a McKinsey report. Just 2% of medical tech funding was devoted to non-cancer related women’s conditions. Read more.
Investors See Growth Opportunity in Femtech Devoted to Women’s Health
